Brain Tumor AdultNCT07042620
A Study to Test a New Fluid to Improve the Quality of Images Obtained by Using Sound Waves (Ultrasound) During Surgery
A study testing SonoClear(R) System in people with Brain Tumor Adult and Low Grade Glioma (LGG), High Grade Glioma (HGG), run by SonoClear AS at 4 sites in Germany.
Trial summary
The objective of this clinical investigation is to assess the safety and performance of the SonoClear® System. Performance will be assessed by analysis of the contrast-to-noise ratio (CNR) and assessment of image quality by using the Surgeon Image Rating (SIR) Scale. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Brain Tumor Adult, Low Grade Glioma (LGG), High Grade Glioma (HGG), Glioblastoma
- What is being tested?
- SonoClear(R) System
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 15 participants
- Where
- 4 sitesGermany
- Study dates
- 9 Feb 2026to Nov 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- A diffuse malignant glial tumour (high grade (grade III and IV) or low grade (grade I-II)) is suspected from the diagnostic MRI scan
- Pre- or peri-procedural confirmed histopathology of glioma
- ≥18 years of age
- Karnofsky performance status ≥ 70
- Life expectancy of more than 30 days at the time of procedure
- Negative pregnancy test for female subjects of childbearing potential
Who cannot join
- Not able to give consent (e.g., severe cognitive impairment)
- History of brain radiation therapy
- Recent meningitis (within 6 months prior to screening visit)
- Other active infection (within 30 days prior to screening visit)
- Immuno-incompetent patient (e.g., failing immune system due to AIDS)
- Patients taking immune-suppressive medication
Show all 11Show fewer
- Intended biopsy only (meaning cases not suitable for resection)
- Known hypersensitivity to egg protein
- Known hypersensitivity to soybean or peanut protein
- Known Hypersensitivity to glycerol
- Pregnant or lactating females or females who intend to become pregnant during the time of the study
Trial locations and contacts
4 sites in 1 country.
Germany4 sites
Bezirkskrankenhaus Günzburg
Günzburg, 89312
Universitätsklinikum Gießen und Marburg GmbH Standort Marburg
Marburg, 35033
Eberhard Karls Universität Tübingen, Faculty of Medicine, Department of Neurosurgery
Tübingen, 72076
Schwarzwald-Baar Klinikum Villingen-Schwenningen GmbH
Villingen-Schwenningen, 78052
About this study
Official title: Ultrasound Imaging in Brain Tumour Surgery With the Use of SonoClear® System Mimicking Brain Tissue.
The objective of this clinical investigation is to assess the safety and performance of the SonoClear® System. Performance will be assessed by analysis of the contrast-to-noise ratio (CNR) and assessment of image quality by using the Surgeon Image Rating (SIR) Scale.
This is a prospective, multi-centre single arm study where the performance of the SonoClear® System relative to routinely used acoustic coupling fluid is investigated by each patient being their own control. Patients with the diagnosis of high-grade glioma (HGG) and low-grade glioma (LGG) at up to 5 sites in Germany will be included. Additionally, safety data are collected at 72 hours, 30 days and 6 months post procedure.
Read the detailed description
Ultrasound images will be obtained at different timepoints during the operation. First timepoint being after craniotomy (no fluids involved). Second timepoint being when some tumour is left in the bottom of the deeper part of the resection cavity (approximately 80% of tumour removed), and third timepoint being when the surgeon deems resection of the tumour to be completed. At the second and third timepoint ultrasound acquisition will be performed twice at each timepoint. Once with routinely used irrigation fluids (physiologic saline 0.9% / ringer's / lactated ringers' solution) and once with SonoClear® as part of the SonoClear® System
There are two performance related primary endpoints, based on core lab assessments:
- To assess ultrasound images obtained with SonoClear® as part of the SonoClear® System are less influenced by image artefacts compared to images obtained with standard of care irrigation fluid, by measuring the contrast-to-noise ratio (CNR). The CNR is a measure of the relative noise in the image.
- To assess ultrasound images obtained with SonoClear® as part of the SonoClear® System compared to images obtained with standard of care irrigation fluids, by using a qualitative assessment, called the Surgeons Image Rating (SIR) scale. A Panel of Experts will assess the quality of the obtained images by answering 3 questions for each image. For SIR a 1-10 numeric rating scale, is used to measure the quality of the image according to three questions to be answered at the three different timepoints during the operation.
This SIR is designed to explore whether SonoClear® as part of the SonoClear® System having shown to provide better quantitative image quality in the CNR analysis, allows surgeons to detect this improved image quality. Eventually this improved image quality should result in better decision-making during surgery about margins of excision and residual tumour resection.
The primary safety event is defined as any core lab determined major Magnetic Resonance Imaging (MRI) finding when post-operative MRI is compared to pre-operative MRI that was found by the Data Monitoring Committee (DMC) to be serious and probably or definitely related to the study device OR any DMC determined serious adverse event that is probably or definitely related to the study device that occurs within 30 days of the procedure. The primary safety hypothesis declared in ACF-03 study is to prove the primary safety event rate is less than 10%. Success is demonstrated by observing 0 of these events out of 37 subjects exposed to SonoClear® ACF, i.e. the event rate is 0% with an upper two-sided 95% confidence limit less than 10%. With an event rate of less than 10% for major neurotoxicity events that are serious and probably or definitely related to the device, the benefit of a clearer image for the neurosurgeon balances the potentially increased risk. This study expands the number of patients to evaluate the safety outcome. The primary safety event rate will be evaluated also in a total group of 60 patients, 45 using SonoClear® ACF and 15 using the SonoClear® System.
- Being tested
- SonoClear(R) System
- Keywords
- Acoustic Coupling Fluid, Ultrasound imaging in brain tumour surgery, brain tumour surgery
- Medical subject headings
- Glioma, Glioblastoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
SonoClear(R) SystemDevice
The SonoClear(R) System is intended to be used as an acoustic coupling fluid during ultrasound imaging in brain surgery of human beings
| Study group | Role | What they receive |
|---|---|---|
| Ultrasound imaging in brain tumour surgery with the use of SonoClear® System mimicking brain tissue. | Experimental | SonoClear(R) System Receives: Device: SonoClear(R) System |
What is being measured
The primary outcome is the main question the study is designed to answer.
Contrast-to-Noise Ratio (CNR) to quantify the reduction in noise
To show that ultrasound images obtained when using the SonoClear(R) System are less influenced by image artefacts compared to images obtained when using routinely used saline solution measuring the contrast-to-noise ratio (CNR) in the images.
Measured: Ultrasound guided brain tumor resection procedure/surgery
Surgeons Image Rating (SIR) to assess the image quality
Quality assessment of the images is done by the core-lab in a blinded manner using the Surgeon Image Rating (SIR) scale, a 1-10 rating scale to score the quality of the image according to 3 questions at different time points during the operation. First timepoint being after craniotomy (no fluids involved). The second time point is when some tumour is left in the bottom of the deeper part of the resection cavity (approximately 80% of tumour removed), and the third time point being when the surgeon deems resection of the tumour to be completed.
Measured: Ultrasound guided brain tumor resection procedure/surgery
Adverse events up to 6 months post procedure
The primary safety hypothesis declared in ACF-03 study is to prove the primary safety event rate is less than 10%. Success is demonstrated by observing 0 of these events out of 37 subjects exposed to SonoClear® ACF, i.e. the event rate is 0% with an upper two-sided 95% confidence limit less than 10%. With an event rate of less than 10% for major neurotoxicity events that are serious and probably or definitely related to the device, the benefit of a clearer image for the neurosurgeon balances the potentially increased risk. This study expands the number of patients to evaluate the safety outcome. The primary safety event rate will be evaluated also in a total group of 60 patients, 45 using SonoClear® ACF and 15 using the SonoClear® System.
Measured: safety data are collected up to 6 months post procedure
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jun 2025
- Study start9 Feb 2026
- Primary completionJun 2026 (estimated)
- Study completionNov 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Brain Tumor AdultStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- A prospective, multi-centre single arm study
- Masking
- None (open label)
- Enrolment
- 15 participants (estimated)
Sponsor and investigators
- Lead sponsor
- SonoClear AS
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07042620
- Sponsor's protocol ID
- ACF-03-02
- Status last verified
- May 2026
- First submitted
- 12 Jun 2025
- Last updated
- 14 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Ultrasound Imaging in Brain Tumour Surgery With the Use of SonoClear® System Mimicking Brain Tissue.
- ClinicalTrials.gov ID
- NCT07042620
- Acronym / sponsor ID
- ACF-03-02
- Keywords
- Acoustic Coupling Fluid, Ultrasound imaging in brain tumour surgery, brain tumour surgery
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 15 participants (estimated)
- Lead sponsor
- SonoClear ASIndustry (pharma, biotech, devices)
- Study start
- 9 Feb 2026 (actual)
- Primary completion
- Jun 2026 (estimated)
- Study completion
- Nov 2026 (estimated)
- First posted
- 29 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this clinical investigation is to assess the safety and performance of the SonoClear® System. Performance will be assessed by analysis of the contrast-to-noise ratio (CNR) and assessment of image quality by using the Surgeon Image Rating (SIR) Scale.
This is a prospective, multi-centre single arm study where the performance of the SonoClear® System relative to routinely used acoustic coupling fluid is investigated by each patient being their own control. Patients with the diagnosis of high-grade glioma (HGG) and low-grade glioma (LGG) at up to 5 sites in Germany will be included. Additionally, safety data are collected at 72 hours, 30 days and 6 months post procedure.
Detailed description
Ultrasound images will be obtained at different timepoints during the operation. First timepoint being after craniotomy (no fluids involved). Second timepoint being when some tumour is left in the bottom of the deeper part of the resection cavity (approximately 80% of tumour removed), and third timepoint being when the surgeon deems resection of the tumour to be completed. At the second and third timepoint ultrasound acquisition will be performed twice at each timepoint. Once with routinely used irrigation fluids (physiologic saline 0.9% / ringer's / lactated ringers' solution) and once with SonoClear® as part of the SonoClear® System
There are two performance related primary endpoints, based on core lab assessments:
- To assess ultrasound images obtained with SonoClear® as part of the SonoClear® System are less influenced by image artefacts compared to images obtained with standard of care irrigation fluid, by measuring the contrast-to-noise ratio (CNR). The CNR is a measure of the relative noise in the image.
- To assess ultrasound images obtained with SonoClear® as part of the SonoClear® System compared to images obtained with standard of care irrigation fluids, by using a qualitative assessment, called the Surgeons Image Rating (SIR) scale. A Panel of Experts will assess the quality of the obtained images by answering 3 questions for each image. For SIR a 1-10 numeric rating scale, is used to measure the quality of the image according to three questions to be answered at the three different timepoints during the operation.
This SIR is designed to explore whether SonoClear® as part of the SonoClear® System having shown to provide better quantitative image quality in the CNR analysis, allows surgeons to detect this improved image quality. Eventually this improved image quality should result in better decision-making during surgery about margins of excision and residual tumour resection.
The primary safety event is defined as any core lab determined major Magnetic Resonance Imaging (MRI) finding when post-operative MRI is compared to pre-operative MRI that was found by the Data Monitoring Committee (DMC) to be serious and probably or definitely related to the study device OR any DMC determined serious adverse event that is probably or definitely related to the study device that occurs within 30 days of the procedure. The primary safety hypothesis declared in ACF-03 study is to prove the primary safety event rate is less than 10%. Success is demonstrated by observing 0 of these events out of 37 subjects exposed to SonoClear® ACF, i.e. the event rate is 0% with an upper two-sided 95% confidence limit less than 10%. With an event rate of less than 10% for major neurotoxicity events that are serious and probably or definitely related to the device, the benefit of a clearer image for the neurosurgeon balances the potentially increased risk. This study expands the number of patients to evaluate the safety outcome. The primary safety event rate will be evaluated also in a total group of 60 patients, 45 using SonoClear® ACF and 15 using the SonoClear® System.
Study design
- Primary purpose
- Other
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- A prospective, multi-centre single arm study
| Arm | Type | Receives |
|---|---|---|
| Ultrasound imaging in brain tumour surgery with the use of SonoClear® System mimicking brain tissue. | Experimental | Device: SonoClear(R) SystemSonoClear(R) System |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- A diffuse malignant glial tumour (high grade (grade III and IV) or low grade (grade I-II)) is suspected from the diagnostic MRI scan
- Pre- or peri-procedural confirmed histopathology of glioma
- ≥18 years of age
- Karnofsky performance status ≥ 70
- Life expectancy of more than 30 days at the time of procedure
Key exclusion criteria (11 listed)
- Not able to give consent (e.g., severe cognitive impairment)
- History of brain radiation therapy
- Recent meningitis (within 6 months prior to screening visit)
- Other active infection (within 30 days prior to screening visit)
- Immuno-incompetent patient (e.g., failing immune system due to AIDS)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| SonoClear(R) SystemThe SonoClear(R) System is intended to be used as an acoustic coupling fluid during ultrasound imaging in brain surgery of human beings | Device | Ultrasound imaging in brain tumour surgery with the use of SonoClear® System mimicking brain tissue. |
Primary outcome
Contrast-to-Noise Ratio (CNR) to quantify the reduction in noise
Time frame: Ultrasound guided brain tumor resection procedure/surgery
To show that ultrasound images obtained when using the SonoClear(R) System are less influenced by image artefacts compared to images obtained when using routinely used saline solution measuring the contrast-to-noise ratio (CNR) in the images.
Surgeons Image Rating (SIR) to assess the image quality
Time frame: Ultrasound guided brain tumor resection procedure/surgery
Quality assessment of the images is done by the core-lab in a blinded manner using the Surgeon Image Rating (SIR) scale, a 1-10 rating scale to score the quality of the image according to 3 questions at different time points during the operation. First timepoint being after craniotomy (no fluids involved). The second time point is when some tumour is left in the bottom of the deeper part of the resection cavity (approximately 80% of tumour removed), and the third time point being when the surgeon deems resection of the tumour to be completed.
Adverse events up to 6 months post procedure
Time frame: safety data are collected up to 6 months post procedure
The primary safety hypothesis declared in ACF-03 study is to prove the primary safety event rate is less than 10%. Success is demonstrated by observing 0 of these events out of 37 subjects exposed to SonoClear® ACF, i.e. the event rate is 0% with an upper two-sided 95% confidence limit less than 10%. With an event rate of less than 10% for major neurotoxicity events that are serious and probably or definitely related to the device, the benefit of a clearer image for the neurosurgeon balances the potentially increased risk. This study expands the number of patients to evaluate the safety outcome. The primary safety event rate will be evaluated also in a total group of 60 patients, 45 using SonoClear® ACF and 15 using the SonoClear® System.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 May 2026.
- Individual participant dataSharing planned: No
Related trials for Brain Tumor Adult
Recruiting
Feasibility Assessment of Adapted Physical Activity in Patients Treated for a Brain Tumor
Brain Tumor Adult
RecruitingPhase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Central Nervous System Neoplasms, Glioblastoma
RecruitingPhase 3
Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant
RecruitingPhase 2
Illuminate: A Clinical Study Evaluating CAR T Immune Cell Therapy (BCB-276) for Patients With Diffuse Intrinsic Pontine Glioma (DIPG).
Diffuse Intrinsic Pontine Glioma, DIPG
RecruitingObservational study
Circulating Biomarkers Repository in Adults Diagnosed With Primary and Metastatic Brain Tumors
Brain Tumor, Primary, Brain Metastases, Adult
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
4 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing SonoClear(R) System in people with Brain Tumor Adult and Low Grade Glioma (LGG), High Grade Glioma (HGG), run by SonoClear AS at 4 sites in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 14 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 4 sites in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Contrast-to-Noise Ratio (CNR) to quantify the reduction in noise (time frame: Ultrasound guided brain tumor resection procedure/surgery). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 May 2026.